Intravenous cidofovir treatment for recalcitrant warts in the setting of a patient with myelodysplastic syndrome

Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment.     

Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years

Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy.     

APPROACHES TO PROMOTING MORE WIDESPREAD PARTICIPATION IN PHYSICAL ACTIVITY

Exercise is associated with a reduced risk of coronary heart disease, has beneficial effects on cardiovascular risk factors, and has other health benefits. No more than 10 per cent to 20 per cent of adults in Australia and other developed countries participate in regular vigorous physical activity, while over 65 per cent of Australian adults are almost totally sedentary. Survey data from the U.S.A. suggest that levels of participation in jogging and walking have increased in the past 10 years but that the proportion of people who take no deliberate exercise has also increased. Large-scale community interventions to promote exercising have not been subject to rigorous evaluation and it is difficult to reach any firm conclusions about the effects of exercise promotion. However, it is possible to identify some of the factors which may influence exercise participation, and there is information from trials of large-scale, multifactorial interventions to reduce cardiovascular risk which provides some helpful guidelines about how it may be useful to proceed. Approaches to increasing levels of exercise participation should emphasise community-based efforts which provide appropriate settings and social support for exercising, making exercise a more appealing and accessible option for large numbers of people; the use of mass media for community education about exercising should be co-ordinated carefully with specific community activities. Personalized fitness instruction, groups and classes should place more emphasis on exercise as a pattern of behaviour to be integrated into a person's way of life and maintained over time; and there is the potential for more widespread and systematic use of self-instructional exercise materials to assist people who wish to exercise independently. Because there exist only limited local research findings and work in other countries does not yet provide conclusive information, research and development priorities for these areas are suggested.     

Biologic variation of common hematologic laboratory quantities in the elderly

Analytic, within-subject, and between-subject biologic variations were estimated for leukocytes, erythrocytes, hemoglobin, hematocrit, mean cell volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin content (MCHC), platelets, and a three-component differential count (lymphocytes, monocytes, and granulocytes in terms of both concentration and percentage of leukocytes) in cohorts of 12 male and 12 female healthy elderly subjects. The assays were performed with an Ortho ELT-800 automated analyzer. The estimates of within-subject biologic variation were similar to published data on young subjects, indicating that this aspect of homeostasis is not compromised in the elderly. The data were used to derive objective analytic goals; goals were surpassed except for assays of erythrocytes, hematocrit, and the derived MCV, MCH, and MCHC. The changes required for serial results to be significantly different were determined and found to be generally valid because most quantities have no heterogeneity of within-subject variation. All quantities had significant individuality; in consequence, conventional population-based reference values are of limited utility, and screening using reference limits will not detect latent or early disease in many subjects.